Alzheimer’s digest - 2021

Alzheimer’s digest - 2021

BioVie announced closing of acquisition of biopharma assets from privately held NeurMedix

NE3107 (ERK inhibitor) – BioVie/ NeurMedix

  • The acquired assets include NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation
  • NE3107 recently received IND approval from FDA pivotal Phase 3 initiation
  • Enrollment expected to start in mid-2021

“The closing of this acquisition is a major milestone for BioVie, one that expands the Company’s pipeline into several areas of unmet medical need with significant market potential,” said Cuong V. Do, President & CEO of BioVie. “We look forward to executing our clinical development plan and realizing the full potential of these important assets” (For full story click here)

NeurMedix acquisition expands BioVie pipeline into several areas with significant market potential

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share

CI Scientists Commentary:

  • While AD has specific disease features including amyloid-β accumulation and tau pathology, there has been growing evidence linking inflammation and insulin resistance to AD dementia and progression
  • NE3107 halts neuroinflammation and insulin resistance, and thereby may halt the progression of Alzheimer’s disease could represent an entirely new medical approach to treating Alzheimer’s disease
  • Current anti-inflammatory agents limit their chronic use for reasons of toxicity and poor BBB penetration. NE3107 addresses these limitations as a highly BBB permeable drug, with low potential for toxicity that targets the major inflammation signaling pathways

– Dr. Kowndinya, CI Scientists

Home